Ziconotide Acetate Suppliers & Bulk Manufacturers
Available Forms: Intrathecal solution
Available Strengths: 25 mcg/mL
Reference Brands: Prialt (USA/EU)
Category:
Critical Care
Ziconotide Acetate is available in Intrathecal solution
and strengths such as 25 mcg/mL.
Sourced from GMP-certified and ISO-compliant manufacturers, this API meets
global pharmacopeia standards (USP/EP/JP as applicable). Ideal for pharmaceutical
formulation and commercial manufacturing, Ziconotide Acetate is supplied in
bulk quantities with complete regulatory support including DMF, COA, and MSDS.
|
Technical Specifications & Supply Details
|
| Lead Time |
7 to 60 days (depending on batch size & schedule) |
| MOQ |
As per manufacturer’s batch size |
| COA |
Available with every batch |
| Regulatory Dossier / DMF |
Available upon request |
| Export Documentation |
FSC, COA, Manufacturing License, Product Permission |
| Standards |
IP, BP, USP |
| Certifications |
WHO-GMP, EU-GMP, USFDA (as applicable) |
Ziconotide Acetate can be exported to over 30 countries across Asia, Africa, Europe,
and Latin America. Flexible packaging, competitive pricing, and a verified supplier
network make Pharmatradz a trusted sourcing partner for pharmaceutical companies
and contract manufacturers worldwide.
Product Description:
Ziconotide, marketed under the brand name Prialt, is an atypical analgesic agent used for the management of severe and chronic pain. It is a synthetic form of an ω-conotoxin peptide derived from the venom of the cone snail (Conus magus). Unlike conventional analgesics, ziconotide is administered intrathecally, directly into the spinal fluid, due to poor efficacy and significant side effects when delivered orally or intravenously.
Intrathecal administration allows ziconotide to selectively block N-type voltage-sensitive calcium channels in the central nervous system, inhibiting the transmission of pain signals without the addictive potential associated with opioids. Because of its invasive delivery method and high cost, ziconotide therapy is generally reserved for patients who are intolerant of or refractory to other treatments, including systemic analgesics, adjunctive therapies, or intrathecal morphine.
Ziconotide’s unique mechanism of action and targeted efficacy make it a valuable option in specialized pain management, especially in cases where conventional therapies fail. Ongoing research aims to explore alternative formulations that could allow less invasive administration while maintaining the drug’s potent analgesic effects. Prialt remains an important treatment for patients requiring intrathecal therapy to manage severe chronic pain.
Disclaimer: By continuing to browse, you agree to the terms of use of this website and the Trade Marks displayed, in compliance with the provisions of the Trademark Act, 1999, Section 30 and 30(1) under 'Fair use.'
The Trade Mark owner has been correctly identified under the heading Manufacturer / TM Owner as required by the Act.
Back to Listing